What we do Eris Lifesciences Limited develops, manufactures, and markets branded pharmaceutical products focused on chronic and acute therapies including cardiology, diabetes, gastroenterology, and dermatology. |
Founded in 2,007 |
Market share Among top 20 Indian pharma companies with leading positions in Anti-Diabetes (6% market share) and Insulins (15%). |
Problem solved Addresses lifestyle-related disorders and chronic illnesses by providing specialist-driven pharmaceutical treatments. |
Top clients or who we serve Serves specialist doctors and hospitals in chronic disease segments; primarily B2B with expanding B2C presence in India and exports to 70+ countries. |
Key management Amit Indubhushan Bakshi (Chairperson & Managing Director) with significant industry experience leading growth and strategic acquisitions. |
Our journey and innovations Since 2007, expanded via multiple divisions, acquisitions, and launched innovative diabetes and dermatology therapies; stepped into biologics and injectables manufacturing. |
Where we operate Primarily India with export presence in Africa, Asia-Pacific, Latin America, Middle East, and emerging EU markets. |
Top products or what we offer Flagship products include anti-diabetes (Dapagliflozin, Linagliptin), insulins, dermatology brands, and biologics; recently launched first-in-market fixed dose combinations. |
Top brands Brands like Gluxit, Racelto, Zomelis, Launched leading insulin Glargine and RHI, multiple top 20 mother brands with significant market shares. |
Raw materials needed Pharmaceutical active ingredients, biologic intermediates, and raw materials for oral solids, injectables, and topical formulations. |
Raw materials supplier Multiple domestic and international suppliers for APIs and biologic inputs; also integrated backward through subsidiaries. |
Recurring vs cyclical contribution Revenue is largely recurring from chronic therapies with growing contributions from newer segments and acquisitions. |
Our industry position Strong competitor with a diversified portfolio; ranks top 5 in anti-diabetes in India and growing international sterile injectables footprint. |
Financial highlights FY25 consolidated revenue ₹2894 crore, PAT ₹351.8 crore; EBITDA margin ~35%; strong operating cash flows and reduced debt ratio. |
Geographical revenue split Revenue primarily from India (~₹2637.5 crore) with significant exports (~₹241.7 crore) across 70+ countries. |
Order book Robust order book growing in EU-CDMO injectables with ₹125-150 crore revenue visibility in FY27 from European clients. |
Whats driving growth Growth driven by portfolio expansion, strategic acquisitions, CDMO business ramp-up, diabetes and biologics innovation, and geographic diversification. |
Our future plans Invest ₹750-800 crore FY26-28 in insulin capacity, sterile injectables, biologics, R&D, and expand EU-CDMO business and product launches. |
Our green promise Committed to sustainability with emphasis on compliance, safety, and optimized manufacturing processes across facilities. |
Our people and values Employs a growing workforce with strong focus on ethical governance, employee development, and inclusive workplace culture. |
Key challenges ahead Managing integration of multiple acquisitions, reducing debt, regulatory compliance across international markets, and competitive pricing pressures. |
Interesting facts Youngest pharma company in India’s top 20 league; rapid growth into complex biologics & injectables in under two decades. |
Risks and strategy Mitigates risks via diversified portfolio, technology investment, geographic spread, strong governance and focused debt reduction strategy. |
